Comparison between PRO FX Tech IPO and Speciality Medicines IPO.
PRO FX Tech IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Speciality Medicines IPO is a SME Bookbuilding proposed to list at BSE SME.
| PRO FX Tech IPO | Speciality Medicines IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | BSE SME |
| Lead Managers | Hem Securities Ltd. | Unistone Capital Pvt.Ltd. |
| Registrar | Cameo Corporate Services Ltd. | Skyline Financial Services Pvt.Ltd. |
| Market Maker | Hem Finlease Pvt.Ltd. | Aikyam Capital Private Limited |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of PRO FX Tech IPO is up to ₹38.21 Cr whereas the issue size of the Speciality Medicines IPO is up to ₹27.28 Cr. The final issue price of PRO FX Tech IPO is ₹87.00 per share and of Speciality Medicines IPO is ₹124.00 per share.
| PRO FX Tech IPO | Speciality Medicines IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹82.00 per share | ₹117.00 per share |
| Issue Price (Upper) | ₹87.00 per share | ₹124.00 per share |
| Issue Price (Final) | ₹87.00 per share | ₹124.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1600 shares | 1000 shares |
| Fresh Issue Size | 43,92,000 shares | 22,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹38.21 Cr | up to ₹27.28 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 43,92,000 shares | 22,00,000 shares |
| Issue Size Total (Amount) | up to ₹38.21 Cr | up to ₹27.28 Cr |
PRO FX Tech IPO opens on Jun 26, 2025, while Speciality Medicines IPO opens on Mar 20, 2026. The closing date of PRO FX Tech IPO and Speciality Medicines IPO is Jun 30, 2025, and Mar 24, 2026, respectively.
| PRO FX Tech IPO | Speciality Medicines IPO | |
|---|---|---|
| Anchor Bid Date | Jun 25, 2025 | |
| Issue Open | Jun 26, 2025 | Mar 20, 2026 |
| Issue Close | Jun 30, 2025 | Mar 24, 2026 |
| Basis Of Allotment (Tentative) | Jul 01, 2025 | Mar 25, 2026 |
| Initiation of Refunds (Tentative) | Jul 02, 2025 | Mar 27, 2026 |
| Credit of Share (Tentative) | Jul 02, 2025 | Mar 27, 2026 |
| Listing date (Tentative) | Jul 03, 2025 | Mar 30, 2026 |
| Anchor Lockin End date 1 | Jul 31, 2025 | |
| Anchor Lockin End date 2 | Sep 29, 2025 |
PRO FX Tech IPO P/E ratio is 9.15, as compared to Speciality Medicines IPO P/E ratio of 9.27.
| PRO FX Tech IPO | Speciality Medicines IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)PRO FX Tech Ltd.'s revenue increased by 17% and profit after tax (PAT) rose by 30% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Standalone)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 68.4 | 59.28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 50.3 | 43.44 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 9.15 | 9.27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹152.28 Cr. | ₹108.94 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 39.71 | 37.85 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 45.55 | 33.39 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.06 | 0.17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹9.51 | ₹13.38 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 33.15 | 28.30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the PRO FX Tech IPO Retail Individual Investors (RII) are offered 15,37,600 shares while in Speciality Medicines IPO retail investors are offered 15,37,600 shares. Qualified Institutional Buyers (QIB) are offered 8,78,400 shares in PRO FX Tech IPO and 21,000 shares in Speciality Medicines IPO.
| PRO FX Tech IPO | Speciality Medicines IPO | |
|---|---|---|
| Anchor Investor Reservation | 13,16,800 shares | 0 shares |
| Market Maker Reservation | 2,40,000 shares | 1,50,000 shares |
| QIB | 8,78,400 shares | 21,000 shares |
| NII | 6,59,200 shares | 10,89,000 shares |
| RII | 15,37,600 shares | 10,90,000 shares |
| Employee | 0 shares | |
| Others | ||
| Total | 43,92,000 shares | 22,00,000 shares |
PRO FX Tech IPO subscribed 25.42x in total, whereas Speciality Medicines IPO subscribed 2.27x.
| PRO FX Tech IPO | Speciality Medicines IPO | |
|---|---|---|
| QIB (times) | 22.03x | 96.24x |
| NII (times) | 56.36x | 1.88x |
| Big NII (times) | 2.50x | |
| Small NII (times) | 0.64x | |
| RII (times) | 14.09x | 0.85x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 25.42x | 2.27x |
